Webcast to begin at 1:00 p.m. ET
Virtual event to include discussions on our lumateperone, ITI-1284, PDE1 inhibitors, and ITI-333 platforms
NEW YORK, Oct. 18, 2021 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced the Company’s Virtual Event featuring highlights of its development programs being held on Wednesday, October 20, 2021 will now begin at 1:00 p.m. ET. The virtual event will run from 1:00 p.m. ET – 4:00 p.m. ET.
The live and archived webcast can be accessed under "Events & Presentations" on the Investor Relations section of the Company's website at www.intracellulartherapies.com. Please log in approximately 5-10 minutes prior to the event to register and to download and install any necessary software.
About Intra-Cellular Therapies
Intra-Cellular Therapies is a biopharmaceutical company founded on Nobel prize-winning research that allows us to understand how therapies affect the inner-workings of cells in the body. The company leverages this intracellular approach to develop innovative treatments for people living with complex psychiatric and neurologic diseases. For more information, please visit www.intracellulartherapies.com.
Contact:
Intra-Cellular Therapies, Inc.
Juan Sanchez, M.D.
Vice President, Corporate Communications and Investor Relations
646-440-9333
Burns McClellan, Inc.
Lisa Burns
cradinovic@burnsmc.com
212-213-0006
MEDIA INQUIRIES:
Sara Franks
Corporate Media Relations W2O Group
sfranks@w2ogroup.com
410-991-4287
